

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Status Change Notice – September 27, 2011

**NOTICE OF STATUS CHANGE**

The accrual objective for Study 2, Group 1 (Arm B) has been met. Therefore, this Group 1 (Arm B) for study 2 is **permanently** closed effective Tuesday, September 27, 2011. Patients currently on study should be followed according to the protocol.

Please note: Study 2, Group 2 (Arm C, patients undergoing surgery) and Group 3 (Arm D, patients with prior anti-VEGF treatment and not undergoing surgery) remain open for accrual.

**Please retain this notice with the protocol.**